Annette Abraham

Annette Abraham

Auto-generated profile, based on publicly available information

Annette Abraham

Affiliations Department of Neurology, Center for Global Health, School of Medicine, Technical University of Munich, Munich, Germany, Centre for Global Health, Department of Community Medicine and Global Health, Institute of Health and Society, University of Oslo, Oslo, Norway

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 February 2020 in Tropical Medicine & International Health
Verified
Journal Article
Open access
PDF file
AAAnnette Abraham
Annette Abraham
VSVeronika Schmidt
Veronika Schmidt
MKMiriam Kaminski
Miriam Kaminski
DSDominik Stelzle
Dominik Stelzle
RMRobert De Meijere
Robert De Meijere
AWAndrea Sylvia Winkler
Andrea Sylvia Winkler
Objectives To report on relevant national surveillance systems of (N)CC and taeniasis (the infection with the adult tapeworm) in the European Union/European Economic Area, and to assess the magnitude of (N)CC occurrence by retrieving information on cases for the period 2000‐2016. Methods (N)CC cases were retrieved via national reporting systems, a systematic literature search, contact with clinicians, and a search for relevant “International Statistical Classification of Diseases and Related Health Problems” (ICD)‐based data. Results Mandatory notification systems for (N)CC were found in Hungary, Iceland and Poland. Ten cases were reported in Poland and none in Hungary and Iceland. Through the systematic literature review and information given by clinicians, 263 individual and 721 aggregated (N)CC cases from 19 European countries were identified. ICD‐based data were obtained from five countries. From 2000 to 2016, a total of 3,489 cases (N)CC cases were coded: 832 in Italy, 8 in Latvia, 357 in Portugal, 2116 in Spain and 176 in Sweden. Conclusion Despite being classified as a possible eradicable disease, (N)CC is still diagnosed across Europe, yet its true extent and impact remain unclear.

31 March 2021 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
AAAnnette Abraham
Annette Abraham
JBJavier A. Bustos
Javier A. Bustos
HCHélène Carabin
Hélène Carabin
RMRobert de Meijere
Robert de Meijere
PSPriyadarshi Soumyaranjan Sahu
Priyadarshi Soumyaranjan Sahu
SSSylvia Sylvia
Sylvia Sylvia
Single brain enhancing lesions (SEL) are the most common presentation of neurocysticercosis (NCC) observed on neuroimaging in people presenting with epileptic seizures not only on the Indian sub-continent and in travelers returning from cysticercosis-endemic regions, but also globally. The aim of this study, which consisted of a systematic review (CRD42019087665), a meta-analysis and an expert group consultation, was to reach consensus on the best anti-seizure medication and anti-inflammatory treatment for individuals with SEL NCC. Standard literature review methods were used, including the Cochrane risk of bias random effects model, meta-analyses were performed and the quality of the body of evidence was rated using GRADE tables. The expert committee included 12 gender and geographically balanced members and recommendations were reached by applying the GRADE framework for guideline development. The 1–1.5-year cumulative incidence of seizure recurrence, cyst resolution or calcification following anti-seizure medication (ASM) withdrawal was not statistically different between ASM of 6, 12 or 24 months. In contrast, in persons whose cyst calcified post treatment, longer ASM decreased seizure recurrence. The cumulative incidence ratio (CIR) 1–1.5 years after stopping ASM was 1.79 95% CI: (1.00, 3.20) for patients given 6 versus 24 months treatment. Duration of treatment had no effect on seizure recurrence in patients whose cyst did not calcify. Anti-inflammatory treatment with corticosteroids in patients treated with ASM compared to patients treated with ASM only showed a statistically significant beneficial effect on seizure reduction (CIR 0.44, 95% CI 0.23, 0.85) and cyst resolution (CIR 1.37, 95%CI: 1.07, 1.75). Our results indicate that ASM in patients with SEL NCC whose cysts resolved can be withdrawn, while patients whose cysts calcified seem to benefit from prolonged anti-seizure medication. Additional corticosteroid treatment was found to have a beneficial effect both on seizure reduction and cyst resolution. Neurocysticercosis is an infection of the brain with the tapeworm Taenia solium. On the Indian sub-continent, the majority of people suffering from neurocysticercosis only show one cyst (larval form of the parasite) in their brain and often present at clinics with epileptic seizures. There is still some debate on the best way to treat these cases to reduce the risk for seizure recurrence. The goal of this study was to review the literature on how well different durations of treatment with anti-seizure medication (ASM), combined or not with corticosteroids, work in order to reduce the seizure recurrence and eliminate the cyst from the brain. The results show that ASMfor 24 months compared to 6 months favors reduced seizure recurrence in patients whose cysts calcified post treatment. Concerning anti-inflammatory treatment, corticosteroids were also found to have beneficial effects on seizure reduction. However, further high-quality randomized controlled trials with adequately long follow-up time are required for better evidence on best drug(s), dose and duration of ASM and corticosteroids for individuals with SEL NCC.